PolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary

Polypid

13/08/2025 14:31

PolyPid Ltd PYPD.OQ reported a quarterly adjusted loss of 78 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.25.  The mean expectation of four analysts for the quarter was for a loss of 55 cents per share. Wall Street expected results to range from -70 cents to -41 cents per share.

Reported revenue was zero​; analysts expected zero.

PolyPid Ltd's reported EPS for the quarter was a loss of 78 cents​.

The company reported a quarterly loss of $9.98 million.

PolyPid Ltd shares had fallen by 3.1% this quarter and gained 12.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 5.3% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for PolyPid Ltd is $13.50, about 74.7% above its last closing price of $3.42

This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.55
-0.78
Missed
Mar. 31 2025
-0.80
-0.70
Beat
Dec. 31 2024
-0.88
-1.09
Missed
Sep. 30 2024
-1.00
-1.22
Missed